Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Symptom Burden in Cancer: Assessment and Management: 2nd Edition
cancers-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Symptom Burden in Cancer: Assessment and Management: 2nd Edition

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Survivorship and Quality of Life".

Deadline for manuscript submissions: 30 June 2026 | Viewed by 1001

Special Issue Editors

Prof. Dr. Sam M. Salek

E-Mail Website
Guest Editor
School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK
Interests: development, evaluation and application of patient-reported outcome (PRO); pharmacoeconomics; cancer syndrome; survivorship; quality of life
Special Issues, Collections and Topics in MDPI journals
Dr. Esther Natalie Oliva

E-Mail Website
Guest Editor
Hematology Department, London North West University Healthcare NHS Trust, London, UK
Interests: myelodysplastic syndromes; acute myeloid leukemia; immune thrombocytopenia; anemia; patient-reported outcomes; quality of life
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Tatyana Ionova

E-Mail Website
Guest Editor
Quality of Life Unit, Saint Petersburg State University Hospital, 190103 Saint Petersburg, Russia
Interests: quality of life; cancer symptom; healthcare; symptom assessment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer and its treatment are accompanied by multiple symptoms that may significantly distress patients and impair their quality of life. These symptoms may delay successful treatment or lead to premature treatment termination. Cancer survivors are at risk of multiple severe and persistent symptoms. The control of disease-related and treatment-related symptoms is an integral component of cancer care. It is well established that optimal symptom management is based on adequate symptom assessment. Implementing patient-reported outcomes to assess symptom burden is greatly significant, and symptom burden surveillance should be performed and managed during cancer treatment. Strategies for assessing symptom burden and its management in patients with various types of cancer is a subject of ongoing investigation. In addition, the burden of symptoms in cancer on family members and family resilience are further focuses of research. Recently, patient empowerment in cancer care in building up patient–provider partnerships through shared decision-making has also been highlighted.

This Special Issue covers areas such as strategies for assessing symptom burden and symptom management in cancer, optimizing cancer care for the improved management of symptoms, the impact of symptom burden on patients with various types of cancers and their families, and patient-centered empowerment strategies for better managing cancer symptoms.

This is the 2nd edition of this Special Issue. You are welcomed to read the published papers at 1st version: Symptom Burden in Cancer: Assessment and Management.

Prof. Dr. Sam M. Salek
Dr. Esther Natalie Oliva
Prof. Dr. Tatyana Ionova
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • symptom burden
  • patient-reported outcomes
  • symptom assessment
  • symptom management
  • cancer survivorship
  • quality of life

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

25 pages, 1851 KB  
Systematic Review
Laser Energy Application in Endoscopic Kidney-Sparing Surgery for Upper Tract Urothelial Carcinoma: A Systematic Review of Oncological Outcomes and Surgical Complications
by Federico Zorzi, Pietro Scilipoti, Stefano Moretto, Carlos Gonzalez-Gonzalez, Nicola Nannola, Daniele Robesti, Andrea Folcia, Marie Chicaud, Stessy Kutchukian, Luigi Candela, Berthe Laurent, Eugenio Ventimiglia, Francesco Montorsi, Alberto Briganti, Andrea Salonia, Luca Villa, Steeve Doizi, Olivier Traxer and Frédéric Panthier
Cancers 2026, 18(5), 821; https://doi.org/10.3390/cancers18050821 - 3 Mar 2026
Viewed by 739
Abstract
Background: Endoscopic kidney-sparing surgery (eKSS) is increasingly adopted for the management of selected patients with upper tract urothelial carcinoma (UTUC). Laser energy is central to tumor ablation during eKSS; however, multiple laser platforms with distinct physical and thermal properties are currently available, and [...] Read more.
Background: Endoscopic kidney-sparing surgery (eKSS) is increasingly adopted for the management of selected patients with upper tract urothelial carcinoma (UTUC). Laser energy is central to tumor ablation during eKSS; however, multiple laser platforms with distinct physical and thermal properties are currently available, and their comparative oncological and safety profiles remain poorly defined. This systematic review aims to summarize the available evidence on oncological outcomes and perioperative complications associated with laser-based endoscopic treatment of UTUC and to explore potential differences according to laser technology. Methods: A systematic literature search identified 25 eligible studies published between 1997 and 2024, including 1344 patients treated with laser-assisted eKSS. All included studies were non-randomized, predominantly retrospective, and characterized by moderate-to-serious risk of bias. Holmium:YAG, Thulium:YAG (thu:YAG, continuous-wave and pulsed), thulium fiber laser (TFL), Neodimio:YAG (Nd:YAG), diode lasers, and combination platforms were reported. Results: Ipsilateral upper tract recurrence was common across all laser categories, with weighted proportions ranging approximately from 27% to 52% and substantial inter-study heterogeneity. Progression and conversion to radical nephroureterectomy (RNU) were relatively infrequent overall, with numerically weighted proportions observed in thu:YAG-based cohorts. Major complications (Clavien–Dindo ≥ III) were rare across all laser technologies, although a trend toward a higher weighted proportions was observed in Ho:YAG- and Nd:YAG-based series. Minor complications were more frequently reported and highly heterogeneous. Conclusions: Available evidence supporting laser selection in endoscopic kidney-sparing management of UTUC is limited and largely descriptive. Thulium:YAG and TFL platforms seem to demonstrate encouraging trends toward lower progression and conversion to-radical-nephroureterectomy rates; however, these findings are derived from heterogeneous, non-comparative studies with limited follow-up. No standard laser platform can currently be recommended over others based on existing data. Prospective, comparative, and methodologically robust studies are required to determine whether laser technologies confer clinically meaningful advantages in oncological control or safety for UTUC treated with eKSS. Full article
(This article belongs to the Special Issue Symptom Burden in Cancer: Assessment and Management: 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop